Based on this evidence, the present study aimed to ascertain whether low adiponectin levels may promote the enrichment of BCSCs, which are known to fuel endocrine resistance and tumor relapse, in a tamoxifen-resistant breast cancer model, thereby contributing to tumor aggressiveness. Here, ADIPOQ is linked to neoplasm.